Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 3/20 | 0.33 |
| ▸ | SERPINA6 | P08185 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.33 |
| ▸ | G6PD | P11413 | 2/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | GUSB | P08236 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.32 |
| ▸ | CYP17A1 | P05093 | 8/20 | 0.32 |
| ▸ | BLM | P54132 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.31 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14037447 | 0.81 | SHBG (0.35) | SHBGSERPINA6LMNAPMP22TSHR | |
| SCHEMBL13347892 | 0.81 | SHBG (0.50) | SHBGSERPINA6LMNAPMP22TSHR | |
| SCHEMBL17013828 | 0.81 | SHBG (0.50) | SHBGSERPINA6LMNAPMP22TSHR | |
| SCHEMBL23566077 | 0.81 | SHBG (0.50) | SHBGSERPINA6LMNAPMP22TSHR | |
| SCHEMBL12945628 | 0.81 | CYP17A1 (0.33) | SHBGSERPINA6LMNAPMP22TSHR | |
| SCHEMBL23563323 | 0.81 | SHBG (0.50) | SHBGSERPINA6LMNAPMP22TSHR | |
| SCHEMBL13175773 | 0.81 | CYP1B1 (0.33) | SHBGSERPINA6LMNAPMP22TSHR | |
| SCHEMBL12945631 | 0.81 | SHBG (0.35) | SHBGSERPINA6LMNAPMP22TSHR | |
| SCHEMBL12945634 | 0.81 | SHBG (0.32) | SHBGSERPINA6LMNAPMP22TSHR | |
| SCHEMBL13319746 | 0.81 | L3MBTL1 (0.48) | SHBGSERPINA6LMNAPMP22TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170266181-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-09-21 | — | — | US | disclosed |
| US-9694005-B2 | Nonsteroidal and steroidal compounds with potent androgen receptor down-regulation and anti prostate cancer activity | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2017-07-04 | — | — | US | disclosed |
| US-20160038476-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | UNIVERSITY OF MARYLAND, BALTIMORE (US) | 2016-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160038476-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | AR, NR5A1, BRCA1 | SHBG 18/4885SERPINA6 450/4885LMNA 674/4885 |
| US-20170266181-A1 | NONSTEROIDAL AND STEROIDAL COMPOUNDS WITH POTENT ANDROGEN RECEPTOR DOWN-REGULATION AND ANTI PROSTATE CANCER ACTIVITY | AR, NR5A1, BRCA1 | SHBG 18/4885SERPINA6 450/4885LMNA 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.